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Abstract
Background: A multitude of definitions determining multidrug resistance (MDR) of Gram-negative organisms exist
worldwide. The definitions differ depending on their purpose and on the issueing country or organization. The
MDR definitions of the European Centre for Disease Prevention and Control (ECDC) were primarily chosen to
harmonize epidemiological surveillance. The German Commission of Hospital Hygiene and Infection Prevention
(KRINKO) issued a national guideline which is mainly used to guide infection prevention and control (IPC) measures.
The Swiss University Hospital Zurich (UHZ) – in absentia of national guidelines – developed its own definition for
IPC purposes. In this study we aimed to determine the effects of different definitions of multidrug-resistance on
rates of Gram-negative multidrug-resistant organisms (GN-MDRO).
Methods: MDR definitions of the ECDC, the German KRINKO and the Swiss University Hospital Zurich were applied
on a dataset comprising isolates of Escherichia coli, Klebsiella pneumoniae, Enterobacter sp., Pseudomonas aeruginosa,
and Acinetobacter baumannii complex. Rates of GN-MDRO were compared and the percentage of patients with a
GN-MDRO was calculated.
Results: In total 11′407 isolates from a 35month period were included. For Enterobacterales and P. aeruginosa, highest
MDR-rates resulted from applying the ‘ECDC-MDR’ definition. ‘ECDC-MDR’ rates were up to four times higher compared
to ‘KRINKO-3/4MRGN’ rates, and up to six times higher compared to UHZ rates. Lowest rates were observed when
applying the ‘KRINKO-4MRGN’ definitions. Comparing the ‘KRINKO-3/4MRGN’ with the UHZ definitions did not show
uniform trends, but yielded higher rates for E. coli and lower rates for P. aeruginosa. On the patient level, the
percentages of GN-MDRO carriers were 2.1, 5.5, 6.6, and 18.2% when applying the ‘KRINKO-4MRGN’, ‘UHZ-MDR’,
‘KRINKO-3/4MRGN’, and the ‘ECDC-MDR’ definition, respectively.
Conclusions: Different MDR-definitions lead to considerable variation in rates of GN-MDRO. Differences arise from the
number of antibiotic categories required to be resistant, the categories and drugs considered relevant, and the
antibiotic panel tested. MDR definitions should be chosen carefully depending on their purpose and local resistance
rates, as definitions guiding isolation precautions have direct effects on costs and patient care.
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Background
The number of gram-negative bacteria that are resistant
to multiple antibiotics is on a constant rise and infections
due to these resistant organisms pose an increasing threat
to the achievements of modern medicine [1, 2]. Besides
standard infection prevention precautions, most hospitals
apply additional transmission-based precautions to reduce
the spread of gram-negative multidrug-resistant organ-
isms (GN-MDRO) from colonized or infected patients to
others. Whether or not care for a patient with a GN-
MDRO needs additional precautions deserves judgement
about the organism’s clinical and epidemiological signifi-
cance [3], as isolation precautions cause high direct and
indirect costs, and were shown to negatively impact sev-
eral dimensions of patient care [4, 5]. It is well known that
the definitions of multidrug resistance (MDR) are neither
harmonized between countries, nor between hospitals in
the same country, nor do guidelines on infection preven-
tion and control (IPC) standards for patients with GN-
MDRO exist to date [6–8].
In Europe, a multitude of definitions for GN-MDRO
with varying purposes do exist: The MDR definitions of
the European Centre for Disease Prevention and Control
(ECDC), published in 2011, were primarily chosen to
harmonize epidemiological surveillance data across
healthcare settings and countries [9]. The ECDC criteria
define MDR as acquired non-susceptibility to at least
one agent in three or more antimicrobial categories. Cat-
egories were constructed with the intent of placing anti-
microbial agents into therapeutically relevant groups and
each category is considered equally relevant.
Germany has a nationwide MDR definition, issued by
the national German Commission of Hospital Hygiene
and Infection Prevention (KRINKO) in 2012, which is pri-
marily used to guide IPC measures [10]. The German
KRINKO defines MDR according to resistance to com-
monly used agents to treat severe infections (i.e. antipseu-
domonal penicillins, extended spectrum cephalosporins,
carbapenems and quinolones). It grades resistance by se-
verity into multidrug resistance to three and four anti-
biotic categories. Isolation precautions are recommended
for all patients with bacterial species resistant to four anti-
biotic categories. For patients with species resistant to
three antibiotic categories, isolation precautions are war-
ranted for patients on high-risk wards (e.g. hemato-
oncology) with Escherichia coli, Klebsiella sp., Enterobac-
ter sp., Pseudomonas aeruginosa, and Acinetobacter
baumanii.
In Switzerland, no national consensus guidelines on
MDR definitions exist to date. Therefore, the University
Hospital Zurich (UHZ) developed its own definition in
2008. These definitions are based on clinical reasoning,
local resistance rates, antibiotic use policies, and inter-
national expert proposals [11]. They are mainly used to
guide IPC measures. The UHZ-guidelines define MDR
as resistance to agents of three out of five antimicrobial
categories including the aminoglycosides. Unlike the
ECDC and KRINKO definitions, the UHZ also includes
the ESBL-phenotype of Enterobacterales (except Escheri-
chia coli) as MDR. E. coli ESBL is not considered a GN-
MDRO following recommendations of the Swiss
national center for infection control (Swissnoso) recom-
mending standard precautions for this specific ESBL-
producing species [12].
Differences in MDR definitions do have an impact on
percentage of gram-negatives considered MDRO and, if
used to guide IPC measures, on patients requiring isola-
tion precautions. The primary aim of this study was to
analyze the impact of the ECDC, KRINKO and UHZ
definitions on the rate of GN-MDRO and the resulting
number of patients characterized as GN-MDRO carriers.
To describe the influence of the different MDR defin-
ition criteria, we applied the definition criteria of ECDC,
KRINKO and UHZ on 11′407 isolates of five common
gram-negative species isolated during a 35 month period
in patients from the UHZ.
Methods
Setting
The University Hospital Zurich, Zurich, Switzerland, is an
950-bed tertiary-care teaching hospital covering all med-
ical specialties except paediatrics and orthopaedics. All
microbiologic samples are tested in the clinical microbiol-
ogy laboratory of the Institute of Medical Microbiology,
University of Zurich, Zurich, Switzerland. The Institute of
Medical Microbiology collects all raw data of disk diffu-
sion antimicrobial susceptibility testing (i.e. inhibition
zone diameters) in a dedicated database (Sirweb, i2a,
Montpellier, France), allowing re-analysis of the raw data.
Isolates and patients
Data from gram-negative rods isolated during a 35-
month period from 1.1.2013 to 1.12.2015 were ana-
lysed. Species analysed comprised Escherichia coli,
Klebsiella pneumoniae, Enterobacter sp., Pseudomonas
aeruginosa, and Acinetobacter baumannii complex. In
order to prevent the exclusion of potential MDR
follow-up isolates which arise from selective pressure
under therapy, we intentionally included all repeat
isolates, neglecting guidelines for analysis and presen-
tation of cumulative antibiograms advising inclusion
of first isolates per patient only [13]. We only in-
cluded isolates with a miminum of the following anti-
biotics tested (required for the ‘UHZ-2008’
definitions, see below): piperacillin/tazobactam, ceftri-
axone (for Enterobacterales), ceftazidime, cefepime,
ertapenem (for Enterobacterales), imipenem, merope-
nem, levofloxacin, ciprofloxacin, amikacin, tobramycin
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and gentamicin. In total, we included 11.407 isolates
from 8.454 patients.
To assess the percentage of patients with colonisation
or infection with a GN-MDRO, we divided the number
of patients with at least one GN-MDRO by the total pa-
tient population included in the study.
Susceptibility testing, detection of resistance mechanisms
and species identification
Only data collected during routine diagnostic testing
was included in this study. For susceptibility testing, the
disc diffusion method according to Kirby-Bauer was
used. Antibiotic discs were obtained from i2a (Montpel-
lier, France). Susceptibility testing was done on Mueller-
Hinton agar (Becton-Dickinson, Franklin Lakes, NJ,
USA) using MacFarland 0.5 from overnight cultures
followed by incubation at 35 °C for 16-18 h. Inhibition
zone diameters were determined and recorded in the au-
tomated Sirweb/Sirscan system (i2a) and interpreted ac-
cording to EUCAST 2015 guidelines [14]. When
EUCAST provided no interpretation guidelines for the
tested antibiotics, CLSI 2015 guidelines were applied
[15]: ceftriaxone, cefepime, ceftazidime and piperacillin/
tazobactam for A. baumannii complex, fosfomycin for
the Enterobacterales, minocycline and tetracycline for
Enterobacterales and A. baumannii complex. Since July
2015 susceptibility to ciprofloxacin and levofloxacin of
Enterobacterales was inferred from the susceptibility
from norfloxacin. Intermediate susceptibility is inter-
preted as resistant.
ESBL production was phenotypically detected by using
screening cut-off values for cephalosporines, followed by
phenotypic confirmation with combination-disk and
double-disk synergy tests and, in non-distinctive cases,
molecular detection of ESBL genes [16, 17]. Carbapene-
mase production was phenotypically detected by using
screening cut-off values for meropenem, followed by
phenotypic confirmation with combination disk tests and
molecular detection of carbepenemase genes [16, 18, 19].
Species identification was performed by matrix-
assisted laser desorption ionization-time of flight mass
spectrometry (MALDI-TOF MS) by the direct transfer-
formic acid method using Bruker Biotyper MALDI-TOF
MS System (Bruker corporation) [20].
MDR-definitions of ECDC, KRINKO and UHZ
The three different MDR definitions per bacterial species
are depicted in Tables 1, 2 and 3.
ECDC definitions, published by Magiorakos et al. in
2011 [9]: The ECDC definitions define multidrug-
resistance, ‘ECDC-MDR’, by non-susceptibility to at least
one agent in three or more of 17 antimicrobial categor-
ies for Enterobacterales, of eight categories for P. aerugi-
nosa, and of nine categories for A. baumanii.
German KRINKO definitions, published in 2012 [10]:
The definition includes two MDR categories, ‘KRINKO-
3MRGN’ and ‘KRINKO-4MRGN’ (MRGN = “Multiresis-
tente gramnegative Stäbchen”, English: “multiresistant
gram-negative rods”). Antibiotics and/or drug categories
that are considered relevant for the MDR-definition are
i) piperacillin, ii) cephalosporins (cefotaxime (or cefe-
pime for P.aeruginosa), ceftazidime) iii) ciprofloxacin,
and iv) carbapenems (meropenem and imipenem).
‘KRINKO-3MRGN’ and ‘KRINKO-4MRGN’ is defined
by resistance to three and four categories, respectively.
Carbapenemase production automatically defines
‘KRINKO-4MRGN’. Other genotypic or phenotypic test
results are not considered relevant. As bacteria of both
MDR categories trigger isolation precautions, we created
the category KRINKO-3/4MRGN comprising species of
KRINKO-3MRGN and KRINKO-4MRGN.
UHZ-definitions, developed in 2008: The UHZ-
definitions classify bacteria to ‘UHZ-MDR’ by nonsuscept-
ibility to one or several agents of at least three out of five
drug categories. In addition, ESBL producing bacteria (ex-
cept E. coli) and carbapenamase producing bacteria are
always classified as ‘UHZ-MDR’, irrespective of the
reported susceptibilities.
Adaptions due to local antibiotic panel
As the Institute of Medical Microbiology of the Univer-
sity of Zurich tested piperacillin/tazobactam but not pi-
peracillin alone (which is required in the KRINKO
definitions), piperacillin resistance of Enterobacterales
and A. baumanii complex was inferred from resistance
to cefotaxime or ceftazidime as it is advised from the
German KRINKO [21]. For the same reason, cefotaxime
was replaced by ceftriaxone for the KRINKO definitions.
Statistical analyses
Differences in group proportions were assessed using
Fisher’s exact test. We used Stata (Version 15.1, Stata-
Corp, College Station, Texas) for statistical analyses. In
order to address incidental findings associated with mul-
tiple testing, only P-values <.001 were considered statis-
tically significant.
Results
We included 4′300 isolates of E. coli, 1′161 isolates of K.
pneumoniae, 610 isolates of Enterobacter sp., 5′158 iso-
lates of P. aeruginosa and 178 isolates of A. baumannii
complex into the analysis. Susceptibility rates for all rele-
vant antibiotics are shown in Additional file 1: Figure S1.
Isolates classified as GN-MDRO
The percentages of isolates per species fulfilling the dif-
ferent MDR definitions are shown in Fig. 1a-e. E.coli, K.
pneumonia, Enterobacter sp. and P.aeruginosa had
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highest rates of multidrug resistance when analysed ac-
cording to the ‘ECDC-MDR’ definitions and lowest rates
when applying the ‘KRINKO-4MRGN’ definitions. Inter-
estingly, the ‘KRINKO-3/4MRGN’ definitions did not
result in uniformly lower or higher MDR rates as com-
pared to UHZ-definitions. Among Enterobacterales the
‘KRINKO-3/4MRGN’ definitions caused higher rates in
MDR E. coli, whereas in K. pneumonia and Enterobacter
sp. rates were comparable. By contrast, the ‘KRINKO-3/
4MRGN’ lead to a lower percentage of MDR P. aerugi-
nosa. In A. baumanii complex all four definitions lead to
comparable MDR rates. P-values of all comparisons are
shown in the Additional file 2: Table S1.
Patients with a GN-MDRO
The percentage of patients colonised or infected with
any GN-MDRO is depicted in Fig. 1f. The percentage is
highest with 18.2% (95% confidence interval (CI), 17.4–
19.0%) when applying the ‘ECDC-MDR’ definition and
lowest with 2.1% (95% CI, 1.8–2.4%) when applying the
‘KRINKO-4MRGN’ definition. From the definitions used
to guide IPC measures, the ‘KRINKO-3/4MRGN’ defin-
ition lead to highest percentages.
Discussion
This study demonstrated major differences in rates of GN-
MDRO when applying the four definitions of the ECDC, the
German KRINKO and the Swiss UHZ. Highest rates of 32–
46% for Enterobacterales, P. aeruginosa and A. baumannii
were found when applying the ‘ECDC-MDR’ definitions,
which were primarily chosen to harmonize epidemiological
surveillance data and are defined by acquired resistance to at
least one antibiotic of any three drug categories. Lowest rates
were induced by applying the ‘KRINKO-4MRGN’ definition
- definitions requiring resistance in all four relevant drug cat-
egories. On the patient level, the ‘ECDC-MDR’ definitions
lead to around thrice as many patients with GN-MDRO
compared to the ‘UHZ-MDR’ and the ‘KRINKO-3/4MRGN’
criteria, and around nine times as many patients compared
to the ‘KRINKO-4MRGN’ criteria.
MDR definitions differ between agencies, countries, and
even between hospitals in a particular country [7]. A survey
among members of the SHEA Research network in 2012/
2013 showed that among 66 hospitals, there were 22 differ-
ent MDR definitions for Enterobacterales [7]. The survey
also revealed that the most commonly selected definition of
MDR for Enterobacterales, A. baumannii complex and P.
aeruginosa was resistance to three or more classes of antimi-
crobials. A literature review in 2006 showed that various
definitions are used for the terms MDR A. baumannii com-
plex and P. aeruginosa [22]. MacKinnon et al. evaluated the
effects of applying three MDR classification metrics on E.
coli isolates from chicken abattoir surveillance samples and
showed that rates were highest when the isolates were non-
susceptible to ≥3 antibiotic drugs (53.3%), followed by non-
susceptible to ≥3 antibiotic categories (i.e. the ‘ECDC-MDR’
definition, 49.4%), and ≥ 3 antibiotic classes (38.5%) [23].
All definitions evaluated in the current study – irre-
spective if used for surveillance reasons or to guide IPC-
precautions - use a ‘category approach’. As expected, the
Table 2 Definition criteria and antibiotic panel for Pseudomonas aeruginosa
Antimicrobial
category
ECDC-MDR KRINKO-3MRGN KRINKO-4MRGN UHZ-MDR
Antipseudomonal
penicillins
Piperacillin/ tazobactam or ticarcillin/
clavulanic acid
Piperacillin a) Piperacillin a) Piperacillin/ tazobactam
Extended spectrum
cephalosporins
Ceftazidime or cefepime Ceftazidime and cefepime Ceftazidime and
cefepime
Ceftazidime and cefepime
Carbapenems Imipenem or meropenem or doripenem Imipenem and meropenem Imipenem and
meropenem
Imipenem or meropenem
Quinolones Ciprofloxacin or levofloxacin Ciprofloxacin Ciprofloxacin Ciprofloxacin and
levofloxacin
Aminoglycosides Amikacin or gentamicin or tobramycin or
netilmicin
≥2 of: Amikacin,
gentamicin, tobramycin
Monobactams Aztreonam
Phosphonic acids Fosfomycin
Polymyxins Colistin or polymyxin B
Definition of MDR Resistant to ≥3 categories Resistant to 3 out of 4
categories
Resistant to all 4
categories
Resistant to 3 out of 5
categories
Abbreviations: ECDC-MDR Multidrug resistance according to the European Centre for Disease Prevention and Control, KRINKO-3MRGN Multidrug resistance to three
antibiotic categories according to the German Commission of Hospital Hygiene and Infection Prevention, KRINKO-4MRGN Multidrug resistance to four antibiotic
categories according to the German Commission of Hospital Hygiene and Infection Prevention, MDR multidrug resistant, UHZ-MDR multidrug resistance according
to University Hospital Zurich guidelines
a) not tested in UHZ, replaced by piperacillin/tazobactam
Italic font: not tested in UHZ or only tested by MIC under special circumstances
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more categories are required to be resistant, the less iso-
lates are considered GN-MDRO. This explains the lowest
rates by applying the ‘KRINKO-4MRGN’ definition de-
fined by resistance to all four tested categories. Regarding
definition criteria requiring resistance to three drug
categories (‘ECDC-MDR’, ‘KRINKO-3/4MRGN’, UHZ-
definitions), differences arise from the number of categor-
ies taken into consideration, and the number of drugs in
the respective drug category required to be resistant. As
expected, the ‘ECDC-MDR’ definitions – with highest
number of relevant drug categories (i.e. up to 17 categor-
ies compared to four or five in Enterobacterales) and low-
est number of antibiotics required to be resistant per drug
category (i.e. one antibiotic compared to up to three) -
lead to considerably higher rates of GN-MDRO than the
other two definition criteria. The difference between
UHZ-MDR and KRINKO-3/4MRGN E. coli (7.8% vs.
11.3%) may be driven by E.coli ESBL producing species
that fulfill the ‘KRINKO-3/4MRGN’ definition, but do not
meet the UHZ-MDR definitions: Although the UHZ cri-
teria generally consider ESBL-producing strains - detected
phenotypically or genotypically - as GN-MDRO, regard-
less of whether the strains fulfill the ‘UHZ-MDR’ criteria
otherwise, the E. coli ESBL isolated are treated as an
exception. E.coli are not per se considered UHZ-MDR be-
cause E.coli has a demonstrated lower transmission poten-
tial than other Enterobacterales, and hence bear a lesser
potential for outbreaks [24, 25]. In comparison, e.g. K.
pneumoniae shows a clear trend to spread clonally within
healthcare institutions, and K. pneumoniae ESBL are con-
sidered UZH-MDR irrespective ot other drug resistances
being presented or not [26].
When applying the three definition criteria used to
guide IPC measures (both KRINKO and the UHZ def-
inition) on the patient level, only 2% of patients are
colonized or infected with bacteria fulfilling the
‘KRINKO-4MRGN’ definitions. The UHZ-definition
and the ‘KRINKO-3/4MRGN’ definition lead to 5.6
and 6.6% of patients with an GN-MDRO, respectively.
The difference between the UHZ-definitions and the
‘KRINKO-3/4MRGN’ definition is driven by the differ-
ence in MDR E. coli, the only species in which UHZ-
definitions showed lower results than KRINKO-3/
4MRGN. This relative difference of 16% between UHZ-
and ‘KRINKO-3/4MRGN’ definitions still is considerable
when taking into account that most hospitals would
assign patients with GN-MDRO to a single room and
ask for resource intensive isolation precautions. A
Table 3 Definition criteria and antibiotic panel for Acinetobacter baumannii complex
Antimicrobial category ECDC-MDR KRINKO-3MRGN KRINKO-4MRGN UHZ-MDR
Antipseudomonal
penicillins
Piperacillin/ tazobactam
or ticarcillin/ clavulanic acid
Piperacillin a) Piperacillin a) Piperacillin/ tazobactam
Extended spectrum
cephalosporins
Cefotaxime or ceftriaxone
or ceftazidime or cefepime
Cefotaxime b) or ceftazidime Cefotaxime b) or ceftazidime Ceftazidime and
cefepime
Carbapenems Imipenem or meropenem
or doripenem
Imipenem or meropenem Imipenem or meropenem Imipenem or
meropenem
Quinolones Ciprofloxacin or
levofloxacin
Ciprofloxacin Ciprofloxacin Ciprofloxacin and
levofloxacin
Aminoglycosides Amikacin or gentamicin
or tobramycin or netilmicin
≥2 of: Amikacin,
gentamicin, tobramycin
Folate pathway
inhibitors
Trimethoprim/
sulphamethoxazol
Penicillins plus beta-
lactamase-inhibitors
Ampicillin/ sulbactam
Polymyxins Colistin or polymyxin B
Tetracyclines Tetracycline or doxycycline
or minocycline
Definition of MDR Resistant to ≥3 categories Resistant to antipseudomonal
penicillin and cephalosporin-group
and quinolone and susceptible to
carbapenems
Resistant to all 4 categories or If
a carbapenem is resistant all
Acinetobacter are interpreted
as 4MRGN or Acinetobacter with
carbapenemase production
Resistant to 3 out
of 5 categories
Abbreviations: ECDC-MDR Multidrug resistance according to the European Centre for Disease Prevention and Control, KRINKO-3MRGN Multidrug resistance to three
antibiotic categories according to the German Commission of Hospital Hygiene and Infection Prevention, KRINKO-4MRGN Multidrug resistance to four antibiotic
categories according to the German Commission of Hospital Hygiene and Infection Prevention, MDR Multidrug resistant, UHZ-MDR multidrug resistance according
to University Hospital Zurich guidelines
a) as piperacillin/tazobactam and not piperacillin was tested: Resistance to ceftriaxone and/or ceftazidime was interpreted as resistance to piperacillin (15)
b) as cefotaxime was not tested, ceftazidime replaces cefotaxime
Italic font: not tested in UHZ or only tested by MIC under special circumstances
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Fig. 1 Percentages of isolates and patients fulfilling the respective GN-MDRO criteria. Light grey bars are the percentage of isolates classified as
GN-MDRO according to the respective definition criteria. Grey bars are the percentage of patients who ever had an isolate fulfilling the respective
definition criteria. The definition criteria are shown in Tables 1, 2 and 3. ECDC-MDR, multidrug resistance according to the European Centre for
Disease Prevention and Control; GN-MDRO, Gram-negative multirdrug resistant organisms; KRINKO-3/4MRGN, multidrug resistance defined as
resistance to three or four antibiotic categories according to the German Commission of Hospital Hygiene and Infection Prevention; KRINKO-
4MRGN, multidrug resistance defined as resistance to four antibiotic categories according to the German Commission of Hospital Hygiene and
Infection Prevention; UHZ-MDR, multidrug resistance according to University Hospital Zurich guidelines
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study by Tran et al. showed that patients isolated for
methicillin resistant Staphylococcus aureus in compari-
son to non-isolated patients had longer lengths of
hospital stay, stayed in hospital longer than expected, and
had higher costs [5]. Direct costs of isolation precautions
in a Swiss hospital were calculated to sum up to 158 $
per day [4].
Our study has limitations. First, it was conducted in
a low prevalence country for GN-MDRO and our re-
sults might not be similarly applicable to higher
prevalence regions. Second, the antibiotic panel tested
has a critical influence on resistance rates, especially
for the ‘ECDC-MDR” definition. Broadly speaking, the
higher the number of antibiotics on the panel the
higher the probability that an isolate is considered
‘ECDC-MDR’. The ECDC emphazises the necessity of
testing an adequate number of antimicrobial agents in
order to effectively apply the ECDC-definitions, but
even in a high-income country like Switzerland, the
antibiotic panel tested for Enterobacterales is smaller
than the proposed ECDC panel. This is due to finan-
cial restrictions that force clinical laboratories to work
at least cost-neutral. Also, manufacturers of microdi-
lution assays often preset the antibiotic panel tested.
These facts extrinsicaly cause differences in ‘ECDC-
MDR’ rates and preclude comparisons between hospi-
tals with different antibiotic panel. Still, as we were
unable to identify other studies trying to answer this
research question, our study provides unique data
demonstrating the difference of GN-MDRO rates after
applying diverse resistance definitions to a “real-
world” clinical database with a “real-world” antibiotic
panel.
Conclusion
By demonstrating that rates of gram-negatives classi-
fied as MDRO differ considerably depending on the
applied MDR-criteria, we consider choosing definition
criteria carefully depending on their purpose to be of
high importance. For determining definitions directing
isolation precautions, local resistance rates and epidemio-
logical priorities as well as available resources should be
taken into consideration. The additional effort and costs
of isolation precautions should be in due proportion to
the expected benefit. GN-MDRO abundantly present in
the population likely do not require isolation precautions.
MDR definitions should be consistent, clearly communi-
cated, and reviewed regularly. More studies applying the
different definitions on datasets from high prevalence re-
gions or testing the effects of other definitions would pro-
vide useful information to further get insight in the
landscape of GN-MDRO worldwide. Additionally, the ef-
fect of EUCASTs new definitions of susceptibility testing
categories would be interesting to evaluate [27].
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